Literature DB >> 7956270

The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods and baseline characteristics of study patients.

F Ederer1, D E Gaasterland, E K Sullivan.   

Abstract

Medical therapy has been the standard initial treatment for open-angle glaucoma. When some visual field has been lost and maximum tolerated and effective medical therapy does not succeed in controlling the disease, the patient is considered to have advanced glaucoma, and the first of a potential sequence of surgical treatments is usually indicated. Little is known about the long-term course and prognosis of advanced glaucoma or about the long-term effectiveness of sequential surgical treatments in controlling the disease and preventing vision loss and blindness. The Advanced Glaucoma Intervention Study was designed to study, in advanced glaucoma, the long-term clinical course and prognosis, and, in a randomized trial, the comparative outcomes of two sequences of surgical treatments. Toward these goals, 789 eyes in 591 patients were enrolled at 11 clinical centers between 1988 and 1992. Follow-up will continue until 1996. Eyes were randomly assigned to one of two sequences of surgical treatments. One sequence begins with argon laser trabeculoplasty (ALT), is followed by trabeculectomy, an incisional surgical filtering procedure, should ALT fail to control the disease, and by a second trabeculectomy should the first trabeculectomy fail. The other sequence begins with trabeculectomy, is followed by ALT should the trabeculectomy fail, and by a second trabeculectomy should ALT fail. The main outcome of interest is visual function (visual field and visual acuity). Other important outcomes are intraocular pressure, complications of surgery, time to treatment failure, and extent of need for additional medical therapy. We present in this paper the rationale, objectives, design and methods of the study, and the baseline characteristics of study patients and eyes.

Entities:  

Mesh:

Year:  1994        PMID: 7956270     DOI: 10.1016/0197-2456(94)90046-9

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  51 in total

1.  The rate of visual field change in the ocular hypertension treatment study.

Authors:  Shaban Demirel; Carlos Gustavo V De Moraes; Stuart K Gardiner; Jeffrey M Liebmann; George A Cioffi; Robert Ritch; Mae O Gordon; Michael A Kass
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-01-25       Impact factor: 4.799

2.  Normal visual field test results following glaucomatous visual field end points in the Ocular Hypertension Treatment Study.

Authors:  John L Keltner; Chris A Johnson; Richard A Levine; Juanjuan Fan; Kimberly E Cello; Michael A Kass; Mae O Gordon
Journal:  Arch Ophthalmol       Date:  2005-09

Review 3.  Detection of visual field progression in glaucoma with standard achromatic perimetry: a review and practical implications.

Authors:  Kouros Nouri-Mahdavi; Nariman Nassiri; Annette Giangiacomo; Joseph Caprioli
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-08-26       Impact factor: 3.117

4.  Gravitational Influence on Intraocular Pressure: Implications for Spaceflight and Disease.

Authors:  Alex S Huang; Michael B Stenger; Brandon R Macias
Journal:  J Glaucoma       Date:  2019-08       Impact factor: 2.503

5.  A comparison of cup-to-disc ratio estimates by fundus biomicroscopy and stereoscopic optic disc photography in the Tema Eye Survey.

Authors:  J C Mwanza; D S Grover; D L Budenz; L W Herndon; W Nolan; J Whiteside-de Vos; G Hay-Smith; J R Bandi; K A Bhansali; L A Forbes; W J Feuer; K Barton
Journal:  Eye (Lond)       Date:  2017-04-07       Impact factor: 3.775

6.  Series length used during trend analysis affects sensitivity to changes in progression rate in the ocular hypertension treatment study.

Authors:  Stuart K Gardiner; Shaban Demirel; Carlos Gustavo De Moraes; Jeffrey M Liebmann; George A Cioffi; Robert Ritch; Mae O Gordon; Michael A Kass
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-15       Impact factor: 4.799

7.  The NEIGHBOR consortium primary open-angle glaucoma genome-wide association study: rationale, study design, and clinical variables.

Authors:  Janey L Wiggs; Michael A Hauser; Wael Abdrabou; Robert Rand Allingham; Donald L Budenz; Elizabeth Delbono; David S Friedman; Jae H Kang; Douglas Gaasterland; Terry Gaasterland; Richard K Lee; Paul R Lichter; Stephanie Loomis; Yutao Liu; Cathy McCarty; Felipe A Medeiros; Sayoko E Moroi; Lana M Olson; Anthony Realini; Julia E Richards; Frank W Rozsa; Joel S Schuman; Kuldev Singh; Joshua D Stein; Douglas Vollrath; Robert N Weinreb; Gadi Wollstein; Brian L Yaspan; Sachiko Yoneyama; Don Zack; Kang Zhang; Margaret Pericak-Vance; Louis R Pasquale; Jonathan L Haines
Journal:  J Glaucoma       Date:  2013-09       Impact factor: 2.503

8.  Improving the Feasibility of Glaucoma Clinical Trials Using Trend-Based Visual Field Progression Endpoints.

Authors:  Zhichao Wu; David P Crabb; Balwantray C Chauhan; Jonathan G Crowston; Felipe A Medeiros
Journal:  Ophthalmol Glaucoma       Date:  2019-01-17

9.  Personalized Prediction of Glaucoma Progression Under Different Target Intraocular Pressure Levels Using Filtered Forecasting Methods.

Authors:  Pooyan Kazemian; Mariel S Lavieri; Mark P Van Oyen; Chris Andrews; Joshua D Stein
Journal:  Ophthalmology       Date:  2017-12-02       Impact factor: 12.079

Review 10.  Optic nerve head and fibre layer imaging for diagnosing glaucoma.

Authors:  Manuele Michelessi; Ersilia Lucenteforte; Francesco Oddone; Miriam Brazzelli; Mariacristina Parravano; Sara Franchi; Sueko M Ng; Gianni Virgili
Journal:  Cochrane Database Syst Rev       Date:  2015-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.